Japan tops CPhI 'API Quality' ranking for second year

CPhI data confirms that Japan continues to top global active pharmaceutical ingredients ‘API quality’ rankings, with Japanese respondents bullish on growth in 2022 and forecasting a compound annual growth rate (CAGR) of 14% on average.

The country, despite the global challenges of the last year, also increased its ‘overall competitiveness’ score by 2%, while ranking narrowly behind only Germany and the USA for the quality of its ‘finished product manufacturing’ (8.28) and ‘innovativeness for solid dose’ (7.39).

“Interest from international audiences about how to enter Japan and find regional suppliers and manufacturers remains extremely strong. Demand for generics in particular continues to grow, with companies looking for stable supply chains and alternative suppliers, which is why international interest in networking is so strong. In fact, alongside the matchmaking program, we have an international seminar program addressing the opportunities and challenges when looking to enter Asia’s second largest pharma market,” commented Laura Murina, brand manager, Informa Markets.